[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"5037edde-68fc-4ba2-be19-0dd9cdd215d1","acronym":"INFINITE","url":"https://clinicaltrials.gov/study/NCT03710876","created_at":"2025-02-26T07:43:54.912Z","updated_at":"2025-02-26T07:43:54.912Z","phase":"Phase 3","brief_title":"Efficacy \u0026 Safety of RAd-IFN Administered with Celecoxib \u0026 Gemcitabine in Patients with Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT03710876 - INFINITE","lead_sponsor":"Ferring Ventures Limited","biomarkers":" MSLN • EFEMP1","pipe":"","alterations":" ","tags":["MSLN • EFEMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Adstiladrin (nadofaragene firadenovec-vncg) • celecoxib oral"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 01/21/2019","start_date":" 01/21/2019","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-11-08"},{"id":"15e7f739-98b7-4cb1-a7f5-0dfc757321cf","acronym":"NCI-2020-01520","url":"https://clinicaltrials.gov/study/NCT04348747","created_at":"2021-01-18T21:02:18.854Z","updated_at":"2024-07-02T16:34:26.116Z","phase":"Phase 2","brief_title":"Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer","source_id_and_acronym":"NCT04348747 - NCI-2020-01520","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HER-2 negative","tags":["PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/19/2022","start_date":" 12/19/2022","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 12/15/2026","study_completion_date":" 12/15/2026","last_update_posted":"2024-06-14"},{"id":"7751beea-ed0b-4a4d-8397-acffe8af0a14","acronym":"","url":"https://clinicaltrials.gov/study/NCT02432378","created_at":"2021-01-18T11:38:27.441Z","updated_at":"2024-07-02T16:35:00.114Z","phase":"Phase 1/2","brief_title":"Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines","source_id_and_acronym":"NCT02432378","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX","pipe":"","alterations":" ","tags":["IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Suspended","enrollment":" Enrollment 25","initiation":"Initiation: 09/04/2015","start_date":" 09/04/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-30"},{"id":"8e13ae6f-2afc-43dc-b06c-933f9e190424","acronym":"","url":"https://clinicaltrials.gov/study/NCT04093323","created_at":"2023-11-30T22:15:48.537Z","updated_at":"2024-07-02T16:35:00.203Z","phase":"Phase 2","brief_title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","source_id_and_acronym":"NCT04093323","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 08/22/2025","primary_completion_date":" 08/22/2025","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2024-05-30"},{"id":"6ed096db-209e-48e7-96fd-e871bccf6c82","acronym":"GIHSYSU-14","url":"https://clinicaltrials.gov/study/NCT03926338","created_at":"2021-01-18T19:20:49.512Z","updated_at":"2024-07-02T16:35:16.078Z","phase":"Phase 2","brief_title":"Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer","source_id_and_acronym":"NCT03926338 - GIHSYSU-14","lead_sponsor":"Sun Yat-sen University","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/10/2019","start_date":" 05/10/2019","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2030","study_completion_date":" 04/01/2030","last_update_posted":"2024-03-06"},{"id":"4b5fa737-38c5-463a-9236-f514b088e5af","acronym":"AflacST1502","url":"https://clinicaltrials.gov/study/NCT02574728","created_at":"2021-01-18T12:28:46.275Z","updated_at":"2024-07-02T16:35:17.957Z","phase":"Phase 2","brief_title":"Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors","source_id_and_acronym":"NCT02574728 - AflacST1502","lead_sponsor":"Emory University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • sirolimus • celecoxib oral • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-02-23"},{"id":"dd3d4d67-0859-4f46-b395-3bf18f2f7dc2","acronym":"RACIN","url":"https://clinicaltrials.gov/study/NCT03728179","created_at":"2021-01-18T18:16:01.559Z","updated_at":"2024-07-02T16:35:18.689Z","phase":"Phase 1","brief_title":"RACIN in Patients With Advanced TIL-negative Solid Tumors","source_id_and_acronym":"NCT03728179 - RACIN","lead_sponsor":"Centre Hospitalier Universitaire Vaudois","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • aspirin • celecoxib oral • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 01/16/2019","start_date":" 01/16/2019","primary_txt":" Primary completion: 10/27/2023","primary_completion_date":" 10/27/2023","study_txt":" Completion: 10/27/2023","study_completion_date":" 10/27/2023","last_update_posted":"2024-02-20"},{"id":"c4fd9f6b-4ad6-48a9-9c1e-9995ab8936fb","acronym":"SINCERE","url":"https://clinicaltrials.gov/study/NCT05933980","created_at":"2023-07-06T16:10:28.810Z","updated_at":"2024-07-02T16:35:20.675Z","phase":"Phase 2","brief_title":"Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer","source_id_and_acronym":"NCT05933980 - SINCERE","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • Stivarga (regorafenib) • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 12/19/2023","start_date":" 12/19/2023","primary_txt":" Primary completion: 09/20/2025","primary_completion_date":" 09/20/2025","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2024-02-06"},{"id":"0fab3fc5-371c-4513-860f-4d767f471226","acronym":"","url":"https://clinicaltrials.gov/study/NCT05281276","created_at":"2022-03-16T16:55:17.375Z","updated_at":"2024-07-02T16:35:26.269Z","phase":"Phase 1","brief_title":"Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)","source_id_and_acronym":"NCT05281276","lead_sponsor":"Taipei Medical University Shuang Ho Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide) • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-14"},{"id":"ecd4233d-652a-44e6-a88e-15a5d3f5f1d7","acronym":"DETECT","url":"https://clinicaltrials.gov/study/NCT05578287","created_at":"2022-10-13T17:58:13.870Z","updated_at":"2024-07-02T16:35:26.854Z","phase":"Phase 2","brief_title":"RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05578287 - DETECT","lead_sponsor":"Sun Yat-sen University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • capecitabine • Aidixi (disitamab vedotin) • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/25/2025","study_completion_date":" 12/25/2025","last_update_posted":"2023-12-07"},{"id":"307f58ff-e40c-4fdc-bf96-004db83003a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06076837","created_at":"2023-10-11T16:12:25.578Z","updated_at":"2024-07-02T16:35:33.893Z","phase":"Phase 1","brief_title":"The Seven Trial: Exploiting the Unfolded Protein Response","source_id_and_acronym":"NCT06076837","lead_sponsor":"HonorHealth Research Institute","biomarkers":" CEACAM5 • MUC16","pipe":"","alterations":" ","tags":["CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • albumin-bound paclitaxel • balstilimab (AGEN2034) • botensilimab (AGEN1181) • celecoxib oral"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-11"},{"id":"59bdfa97-7b2e-46bf-97c1-23ab33821d5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04081389","created_at":"2021-01-18T19:59:01.001Z","updated_at":"2024-07-02T16:35:37.452Z","phase":"Phase 1","brief_title":"Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer","source_id_and_acronym":"NCT04081389","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin • Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 05/24/2022","primary_completion_date":" 05/24/2022","study_txt":" Completion: 02/27/2023","study_completion_date":" 02/27/2023","last_update_posted":"2023-09-11"},{"id":"99deeabc-01ac-4512-acfb-0ee835276399","acronym":"","url":"https://clinicaltrials.gov/study/NCT00846430","created_at":"2021-01-18T03:13:18.115Z","updated_at":"2024-07-02T16:35:38.602Z","phase":"Phase 2","brief_title":"Medical Treatment of \"High-Risk\" Neurofibromas","source_id_and_acronym":"NCT00846430","lead_sponsor":"Spectrum Health Hospitals","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vincristine • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 04/01/2017","primary_completion_date":" 04/01/2017","study_txt":" Completion: 05/01/2017","study_completion_date":" 05/01/2017","last_update_posted":"2023-08-30"},{"id":"8c0cad02-2897-4ee2-8f3a-675298ec5be6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00090974","created_at":"2021-01-18T00:16:30.416Z","updated_at":"2024-07-02T16:35:45.534Z","phase":"Phase 3","brief_title":"Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer","source_id_and_acronym":"NCT00090974","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • exemestane • celecoxib oral"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 01/26/2005","start_date":" 01/26/2005","primary_txt":" Primary completion: 01/30/2013","primary_completion_date":" 01/30/2013","study_txt":" Completion: 01/30/2013","study_completion_date":" 01/30/2013","last_update_posted":"2023-06-15"},{"id":"6ca52df8-638a-4323-b022-d68d886a646a","acronym":"ERLO-XIB","url":"https://clinicaltrials.gov/study/NCT02748707","created_at":"2021-01-18T13:27:59.774Z","updated_at":"2024-07-02T16:36:11.256Z","phase":"Phase 2","brief_title":"Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study","source_id_and_acronym":"NCT02748707 - ERLO-XIB","lead_sponsor":"Tata Memorial Hospital","biomarkers":" EGFR • TP53","pipe":"","alterations":" ","tags":["EGFR • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • celecoxib oral"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 08/18/2015","start_date":" 08/18/2015","primary_txt":" Primary completion: 02/12/2018","primary_completion_date":" 02/12/2018","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2022-04-28"},{"id":"d71e2201-49b6-4836-82b8-2c176d8657e0","acronym":"HFS","url":"https://clinicaltrials.gov/study/NCT05327751","created_at":"2022-04-14T12:54:02.941Z","updated_at":"2024-07-02T16:36:12.736Z","phase":"Phase 3","brief_title":"Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer","source_id_and_acronym":"NCT05327751 - HFS","lead_sponsor":"Tanta University","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-04-14"},{"id":"2ef799d3-1ede-4380-b63e-812810bb7c1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03403634","created_at":"2021-01-18T16:47:42.513Z","updated_at":"2024-07-02T16:36:16.175Z","phase":"Phase 2a","brief_title":"Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver","source_id_and_acronym":"NCT03403634","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1 • MSI • CD8","pipe":" | ","alterations":" MSI-H/dMMR • RAS wild-type","tags":["PD-L1 • MSI • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/19/2018","start_date":" 04/19/2018","primary_txt":" Primary completion: 12/23/2020","primary_completion_date":" 12/23/2020","study_txt":" Completion: 08/29/2021","study_completion_date":" 08/29/2021","last_update_posted":"2022-03-02"},{"id":"6ed25a2c-816b-431f-9aca-3d4920a47247","acronym":"COLA","url":"https://clinicaltrials.gov/study/NCT02484664","created_at":"2021-01-18T11:58:12.435Z","updated_at":"2024-07-02T16:36:18.233Z","phase":"Phase 2","brief_title":"COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC","source_id_and_acronym":"NCT02484664 - COLA","lead_sponsor":"Brigham and Women's Hospital","biomarkers":" VEGFD","pipe":"","alterations":" ","tags":["VEGFD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 06/15/2016","start_date":" 06/15/2016","primary_txt":" Primary completion: 11/19/2018","primary_completion_date":" 11/19/2018","study_txt":" Completion: 11/19/2018","study_completion_date":" 11/19/2018","last_update_posted":"2022-01-20"},{"id":"eae090bd-dc86-4985-9c25-950f6174910f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00033371","created_at":"2021-01-18T00:01:08.058Z","updated_at":"2024-07-02T16:36:40.614Z","phase":"Phase 2","brief_title":"Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis","source_id_and_acronym":"NCT00033371","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 205","initiation":"Initiation: 12/13/2001","start_date":" 12/13/2001","primary_txt":" Primary completion: 02/24/2009","primary_completion_date":" 02/24/2009","study_txt":" Completion: 03/24/2009","study_completion_date":" 03/24/2009","last_update_posted":"2020-09-29"},{"id":"e94bc33f-4b68-4cea-9cad-25269ea1d5ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT00020878","created_at":"2021-02-11T09:52:26.698Z","updated_at":"2024-07-02T16:36:42.420Z","phase":"Phase 2","brief_title":"Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers","source_id_and_acronym":"NCT00020878","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" PTGS2","pipe":" | ","alterations":" PTGS2 expression","tags":["PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 03/01/2001","start_date":" 03/01/2001","primary_txt":" Primary completion: 11/01/2002","primary_completion_date":" 11/01/2002","study_txt":" Completion: 05/01/2009","study_completion_date":" 05/01/2009","last_update_posted":"2020-08-03"},{"id":"d160bba2-646c-4438-b590-5eb0c74d7442","acronym":"","url":"https://clinicaltrials.gov/study/NCT02151448","created_at":"2021-01-18T09:59:55.040Z","updated_at":"2024-07-02T16:36:43.024Z","phase":"Phase 1/2","brief_title":"αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies","source_id_and_acronym":"NCT02151448","lead_sponsor":"David Bartlett","biomarkers":" IL6 • TNFA • CXCL8 • CXCL10 • CXCL12 • IL10 • CXCL11","pipe":" | ","alterations":" IL10 elevation","tags":["IL6 • TNFA • CXCL8 • CXCL10 • CXCL12 • IL10 • CXCL11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/18/2019","primary_completion_date":" 02/18/2019","study_txt":" Completion: 02/18/2019","study_completion_date":" 02/18/2019","last_update_posted":"2020-07-20"},{"id":"b9f08bbc-5a35-410a-8c6d-64e2ae184f3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02280694","created_at":"2021-01-18T10:44:02.145Z","updated_at":"2024-07-02T16:36:50.161Z","phase":"Phase 2","brief_title":"Low Dose Metronomic Poly-chemotherapy for Metastatic CRC","source_id_and_acronym":"NCT02280694","lead_sponsor":"HaEmek Medical Center, Israel","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • celecoxib oral • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2020-02-12"},{"id":"6d4ff3f4-1d80-440a-9e46-70e91aa31170","acronym":"CELEBRIDO","url":"https://clinicaltrials.gov/study/NCT03896113","created_at":"2021-01-18T19:11:21.793Z","updated_at":"2024-07-02T16:36:51.476Z","phase":"Phase 2","brief_title":"Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma","source_id_and_acronym":"NCT03896113 - CELEBRIDO","lead_sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","biomarkers":" CD8 • IDO1 • CD4","pipe":" | ","alterations":" IDO1 expression","tags":["CD8 • IDO1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Unknown status","enrollment":" Enrollment 48","initiation":"Initiation: 11/13/2019","start_date":" 11/13/2019","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2020-01-10"}]